BeNeLuxBelgiumNetherlandsLuxembourg

Prosensa and GlaxoSmithKline expand Duchenne dystrophy alliance

24.06.2010

Leiden - Prosensa NV and British drugmaker GlaxoSmithKline have expanded their cooperation concerning RNA-modulating drugs against Duchenne muscular dystrophy (DMD). Two programmes, covering 4 drug new drug candidates for specific patient subpopulations, have been added to the existing collaboration in DMD. According to the terms of the agreement, GSK has paid two upfront fees and will add milestones dependant on research progress. Within the new programmes, Prosensa and GSK will focus on the skipping of four exons (exon 45, 52, 53, and 55), in addition to their existing programmes that target skipping of exon 51 and 44 (PRO051/GSK2402968 and PRO044). GSK has an option to select two of these additional four compounds for later-stage development and commercialization. Prosensa will retain certain limited European commercialisation rights alongside GSK for the two compounds selected by GSK. For the two compounds not selected by GSK, Prosensa will retain full commercialization rights.

BeNeLux, Tech ReviewBelgiumNetherlandsLuxembourg

12.07.2007

Traditionally, nutritional science has focused largely on nutritional deficiencies and their impact on health and disease. Over the past few decades, research emphasis has gradually shifted to the relationship between...

BeNeLuxBelgiumNetherlandsLuxembourg

12.07.2007

Ghent – Researchers from VIB, Flanders Interuniversity Institute of Biotechnology have found a molecule which shields the skin from damages from UV-B rays and dehydration. They believe that overprotection of Caspase-14 could open...

BeNeLuxBelgiumNetherlandsLuxembourg

11.07.2007

Amsterdam – The Dutch ingredients firm DSM has announced plans to carve out its anti-infectives unit and initiate a partnering strategy with firms in low-cost areas such as India or China. DSM’s anti-infectives business supplies...

BeNeLuxBelgiumNetherlandsLuxembourg

11.07.2007

Leuven – The Belgian regenerative medicine specialist TiGenix has submitted a Marketing Authorisation Application (MAA) to the EMEA with the aim of gaining central approval for ChondroCelect, the company’s product candidate for...

BeNeLuxBelgiumNetherlandsLuxembourg

11.07.2007

Luxembourg – The coming year could be a turning point for research policy in Luxembourg. After years of restructuring following changes in European law and the foundation of Luxembourg University in summer 2003, the Ministry for...

BeNeLuxBelgiumNetherlandsLuxembourg

09.07.2007

Amsterdam – At the end of June, gene therapy specialist Amsterdam Molecular Therapies NV (AMT) raised a50 million in an IPO and private placement at Euronext. The price was at the top of the proposed a8 to a10 bookbuilding range,...

BeNeLuxBelgiumNetherlandsLuxembourg

09.07.2007

Leuven – The Belgian drug developer Thrombogenics has raised a23.9 million through a private placement of 2.2 million shares for the price of a10.80 per share. The offering was 1.5 times oversubscribed and represented about 10%...

BeNeLux, Tech ReviewBelgiumNetherlandsLuxembourg

17.05.2007

Amsterdam – Researchers from the gene therapy company Amsterdam Molecular Therapeutics BV have presented proof of principle data for its gene therapy approach against Acute Intermittent Porphyria, an orphan hereditary disease due...

BeNeLuxBelgiumNetherlandsLuxembourg

16.05.2007

Leiden – Crucell N.V. has entered its rabies monoclonal antibody in Phase I clinical study in India, four months after launching a similar study in the US. The human monoclonal antibody product for the post-exposure prophy­laxis...

BeNeLuxBelgiumNetherlandsLuxembourg

16.05.2007

Leuven – TiGenix, a Belgian biomedical company focused on innovative local treatments for damaged and osteoarthritic joints has gone public at Euronext. The company raised a40 million through the sale of 8 million shares at a5 in...

Displaying results 191 to 200 out of 304

< Previous 191-200 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/19/article/prosensa-and-glaxosmithkline-expand-duchenne-dystrophy-alliance.html

Product of the week

Products

Events

All Events

Current issue

All issues